SECsense Logo

LAVA Therapeutics NV 8-K Report: Key Insights on Corporate Developments

$LVTX
Form 8-K
Filed on: 2025-01-02
Source
LAVA Therapeutics NV 8-K Report: Key Insights on Corporate Developments

Here are the key insights extracted from the provided section of the financial report:

  1. Entity Information:
  • Company Name: LAVA Therapeutics NV
  • CIK Number: 0001840748
  • SEC File Type: 8-K
  • Address: Yalelaan 62, Utrecht, NL 3584 CM
  • Phone Number: +31 85 016 3100
  1. Securities Information:
  • Type of Shares: Common shares
  • Nominal Value: €0.12 per share
  • Stock Symbol: LVTX
  • Exchange: NASDAQ
  1. Filing Date: The report is dated January 1, 2025.
  2. Period of Reporting: The reporting period is a single day, starting and ending on January 1, 2025.
  3. Schema Reference: The filing references a schema file named lvtx-20250101.xsd.
  4. General Context:
  • This filing is classified under the SEC form 8-K, which typically reports unscheduled material events or corporate changes that are of importance to shareholders.

Insights:

  • The company is likely preparing for a significant event or announcement that necessitates the filing of an 8-K, which could impact its stock or operations.
  • The nominal value of shares suggests a focus on maintaining compliance with listing requirements on NASDAQ.
  • As the reporting date is set for the beginning of 2025, this could indicate future plans or strategic changes that the company intends to disclose to investors.

Conclusion:

The report provides a snapshot of LAVA Therapeutics NV as of January 1, 2025, indicating a potential significant corporate event, with necessary disclosures for shareholders and regulatory compliance as a public company. Further details would likely be included in the full 8-K filing to provide insights into the nature of the event or changes being reported.